Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

NCT02955823

Conditions
Diffuse Large B-cells Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia Meldola, Forlì-Cesena, Italy
  • A.O. C. Panico - U.O.C Ematologia e Trapianto Tricase, Lecce, Italy
  • Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS - Ematologia Reggio Emilia, Italy
  • Ospedale Dell'Angelo - U.O. Ematologia Mestre, Venezia, Italy
View all 18 locations
View Trial Details
Completed

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493

Conditions
Cancer, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Dana-Farber Cancer Institute /ID# 207728 Boston, Massachusetts, United States
  • Mayo Clinic - Rochester /ID# 207692 Rochester, Minnesota, United States
  • University of Texas MD Anderson Cancer Center /ID# 207746 Houston, Texas, United States
  • Peter MacCallum Cancer Ctr /ID# 209554 Melbourne, Victoria, Australia
View all 15 locations
View Trial Details
Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

NCT02141282

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 128535 La Jolla, California, United States
  • University of California, Los Angeles /ID# 127262 Los Angeles, California, United States
  • Stanford University School of Med /ID# 126495 Stanford, California, United States
  • Georgetown University Hospital /ID# 127261 Washington D.C., District of Columbia, United States
View all 15 locations
View Trial Details
Completed

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

NCT03456726

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • 1004 Eisai Trial Site Nagoya, Aichi-ken, Japan
  • 1029 Eisai Trial Site Nagoya, Aichi-ken, Japan
  • 1020 Eisai Trial Site Ōta, Gunma, Japan
  • 1007 Eisai Trial Site Sapporo, Hokkaido, Japan
View all 28 locations
View Trial Details

Related conditions